The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Early Data on Novel MK2 Inhibitor to Treat Inflammatory Diseases Promising

Early Data on Novel MK2 Inhibitor to Treat Inflammatory Diseases Promising

June 9, 2022 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2021—The mitogen-activated protein kinase (MAPK) activated protein kinase-2 (MK2) pathway increases pro-inflammatory factors including, but not limited to, tumor necrosis factor (TNF-α), interleukin (IL) 6 and IL-17. A phase 1 study of an irreversible inhibitor of MK2, CC-99677, was presented by Kofi Mensah, MD, PhD, professor of medicine and rheumatology at Yale School of Medicine, New Haven, Conn., and a rheumatologist at Yale New Haven Health/Yale New Haven Hospital, during ACR Convergence 2021.1

You Might Also Like
  • Insights into JAK Inhibitor Use
  • Research Outlines Benefits of bDMARDs to Treat Early RA
  • Tigulixostat Appears Promising for the Treatment of Gout
Also By This Author
  • Health Canada Approves Upadacitinib to Treat Adults with PsA

Methods

This double-blind, placebo-controlled study sought to characterize the safety, pharmacokinetics and pharmacodynamics of CC-99677 in healthy adults (NCT03554993). Thirty-seven healthy adults were enrolled in five dose-level groups, which ranged from 10 mg to 150 mg of CC-99677 or placebo, randomized in a 3:1 ratio of those taking the study drug to those taking placebo. Study participants were given their respective doses daily for 14 days. The primary study outcome was the safety and tolerability of multiple daily doses of CC-99677. The study’s secondary and exploratory outcomes included an assessment of the CC-99677 plasma pharmacokinetic profile and its pharmacodynamic effects, as measured by MK2 target occupancy and ex vivo inhibition of inflammatory cytokines in the whole blood of study participants.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Results

The CC-99677 multiple-dose pharmacokinetic characteristics showed linear, dose-proportional increases in drug uptake from 10 mg to 150 mg using a once-daily dosing schedule over 14 days. In the study, the daily dosing of CC-99677 up to 150 mg was shown to be safe and well tolerated by participants. The drug showed a proportional and linear increase in drug levels across the 14-day study. During the study, once-daily dosing led to the desired effect of a sustained decrease in TNF-α and other cytokines and chemokines throughout the 14 days. This finding was noted for all five dosing groups. Steady-state levels were reached by day 8.

According to Mensah et al., “Daily treatment resulted in dose-dependent increases in target engagement between 10 and 120 mg and plateauing at the 120- and 150 mg-dose levels.” Sustained reductions of TNF-α and other cytokines occurred during dosing.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Overall, this small preliminary study showed that administration of once-daily CC-99677 was safe and well tolerated, with linear pharmacokinetics and sustained reductions of TNF-α and pro-inflammatory cytokines and chemokine creation, making CC-99677 inhibition of MK2 a promising new therapeutic approach to the management of inflammatory diseases. Phase 2 studies in patients with spondyloarthritis are in the planning stages.

Pages: 1 2 | Single Page

Filed Under: ACR Convergence, DMARDs & Immunosuppressives, Drug Updates, Meeting Reports Tagged With: ACR Convergence 2021, CC-99677, mitogen-activated protein kinase (MAPK), tumor necrosis factor

You Might Also Like:
  • Insights into JAK Inhibitor Use
  • Research Outlines Benefits of bDMARDs to Treat Early RA
  • Tigulixostat Appears Promising for the Treatment of Gout
  • Tildrakizumab Promising for Plaque Psoriasis; FDA Approves Adalimumab to Treat Panuveitis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)